Roland Goette Sells 2,438 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Becton, Dickinson and Company Trading Down 0.9%

Shares of Becton, Dickinson and Company stock opened at $182.01 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a market capitalization of $50.15 billion, a P/E ratio of 54.82, a P/E/G ratio of 12.94 and a beta of 0.19. The business has a 50 day moving average price of $157.20 and a 200 day moving average price of $161.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Ratings Changes

BDX has been the topic of a number of recent analyst reports. Piper Sandler increased their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. The Goldman Sachs Group decreased their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Finally, UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $185.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDX. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Becton, Dickinson and Company by 4.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock worth $122,403,000 after acquiring an additional 26,671 shares during the last quarter. Cooke & Bieler LP boosted its stake in Becton, Dickinson and Company by 27.2% in the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after acquiring an additional 240,673 shares during the period. KLP Kapitalforvaltning AS grew its holdings in shares of Becton, Dickinson and Company by 61.2% during the fourth quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock valued at $33,493,000 after purchasing an additional 65,500 shares during the last quarter. Finally, Third View Private Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $4,992,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.